A risk stratification approach to address inpatient beta-lactam allergy labels can safely delabel patients, reduce aztreonam use, and prevent beta-lactam desensitizations

Abstract

Inpatient beta-lactam allergy labels result in increased aztreonam use which is often less efficacious and more costly than preferred agents. Some patients undergo time-consuming desensitizations which prolong length of stay. Addressing inpatient allergy labels can reduce healthcare costs and improve patient outcomes.